April 27, 2021

It seems a little unfair that we often take our type 2 patients off oral medication when they begin basal/bolus insulin use, and it makes even less sense that we won’t give a type 1 patient anything but insulin. Over the past 3 years we have had many studies about the use of metformin, SGLT-2 inhibitors and GLP-1 agonists in type 1 patients. However, both AACE and the ADA have not been in favor of the use of these products with insulin.

This week we have a study from Brenda Oppong, PharmD Candidate, LECOM School of Pharmacy, that looks at the use of a SGLT-2 inhibitor to replace carb counting and in pump patients. The results of this study make a strong argument for adding this oral medicine to a patient with type 1 drug regimen. Check out what Brenda found in her research in our Laterpay feature.

 

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief